Eli Lilly (LLY) is making billions from the weight-loss boom. But it’s no longer simply fighting for a bigger slice of the weight-loss drug market. It’s fighting to stay ahead of a growing army of rivals. Analysts forecast the weight-loss market to generate close to $100 billion in annual sales over the next decade.
Novo Nordisk (NVO) is striking back with Wegovy and Ozempic, while Amgen (AMGN), Roche (RHHBY), and Pfizer (PFE) are crafting new treatments that could shake up the market.
